Internal Medicine, Medical Oncology · Ocala, FL
NPI
1841347655
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1630 SE 18th St Ste 602
Ocala, FL, 34471
Phone (352) 369-0181
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.1M
431,398 services
Medicare patients, 2024
1,296
Average age 75
Drug cost, 2024
$6.4M
2,082 prescriptions
Company payments, 2025
$2,557
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vipul Patel was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 74,460 times for 92 patients. In total Vipul Patel billed 431,398 services in 182 codes, and Medicare paid $6.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 74,460 | 92 | $0.28 | $21K |
| J0897 Injection, denosumab, 1 mg | Office | 20,820 | 160 | $20.49 | $427K |
| J9267 Injection, paclitaxel, 1 mg | Office | 15,173 | 16 | $0.08 | $1,216 |
| J0185 Injection, aprepitant, 1 mg | Office | 14,690 | 26 | $1.29 | $19K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,000 | 13 | $44.65 | $625K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 13,201 | 22 | $2.34 | $31K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 11,840 | 42 | $6.19 | $73K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 7,500 | 60 | $15.67 | $118K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,350 | 79 | $0.09 | $474 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 4,225 | 12 | $31.98 | $135K |
| 36415 Venipuncture Blood Collection | Office | 3,337 | 920 | $8.65 | $29K |
| 85025 Blood Count | Office | 3,196 | 797 | $7.58 | $24K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,820 | 52 | $0.69 | $1,950 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,500 | 19 | $5.84 | $15K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,884 | 42 | $0.07 | $140 |
By year: 2022 $5.5M for 494,847 services; 2023 $5.6M for 431,717 services; 2024 $6.1M for 431,398 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,337 | 920 | $8.65 | $29K |
| 85025 Blood Count | 3,196 | 797 | $7.58 | $24K |
| 85610 Clinical Chemistry | 102 | 12 | $4.20 | $428 |
| 81003 Clinical Chemistry | 100 | 27 | $2.11 | $211 |
| 85045 Blood Count | 26 | 25 | $3.91 | $102 |
| 85046 Blood Count | 16 | 16 | $5.46 | $87.36 |
Medicare prescription drug claims, 2024
In 2024, the drug Vipul Patel prescribed most often to Medicare patients was Anastrozole, with 254 prescriptions and refills. In total Vipul Patel wrote 2,082 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 254 | 633 | 83 | $4,374 |
| Hydroxyurea Generic | 87 | 166 | 23 | $1,630 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 74 | 74 | 26 | $4,424 |
| Eliquis Apixaban | 73 | 97 | 19 | $56K |
| Revlimid Lenalidomide | 72 | 72 | Under 11 | $1.4M |
| Morphine Sulfate Er Morphine Sulfate | 69 | 69 | 15 | $1,440 |
| Letrozole Generic | 65 | 179 | 27 | $1,719 |
| Ondansetron Odt Ondansetron | 62 | 62 | 49 | $1,446 |
| Gabapentin Generic | 62 | 78 | 15 | $548 |
| Prochlorperazine Maleate Generic | 57 | 57 | 30 | $796 |
| Warfarin Sodium Generic | 55 | 85 | Under 11 | $373 |
| Acyclovir Generic | 51 | 65 | Under 11 | $520 |
| Oxycodone Hcl Generic | 51 | 51 | 21 | $1,049 |
| Levothyroxine Sodium Generic | 50 | 81 | 14 | $441 |
| Tamoxifen Citrate Generic | 50 | 110 | 16 | $1,135 |
Brand drugs: 535 claims; generic drugs: 1,547 claims; opioid claims: 278.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vipul Patel $2,557 ($2,557 in general payments such as food, travel and fees) from 37 companies. The largest payer was Pfizer Inc. with $191.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 9 | $191 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 8 | $183 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $167 |
| Merck Sharp & Dohme LLC MRK | 6 | $143 |
| GlaxoSmithKline, LLC. GSK | 9 | $137 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $116 |
| Gilead Sciences, Inc. GILD | 5 | $111 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $106 |
| Abbvie Inc. ABBV | 4 | $89.83 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $88.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.